The development of new, minimally invasive energy-based (laser/phacoemulsification or "phaco") technologies is providing safe and effective, medically necessary, vision-saving treatment to millions of patients, particularly those with cataracts who also seek vision correction surgery. Meanwhile, non-medically necessary, high-cost refractive surgery, such as laser in situ keratomileusis (LASIK) vision correction, continues to increase despite several setbacks.
Overall, more than an estimated 5.5 million directed-energy based (laser/phaco) ophthalmic procedures, including cataract laser surgery, diabetic retinopathy laser surgery, glaucoma/laser trabeculoplasty and laser-based vision correction surgery, were estimated to have been performed in the U.S. in 2013. The advancement of safer and more cost-effective laser-based technologies, such as femtosecond laser cataract surgery and other technological improvements, are expected to improve patient outcomes and drive ophthalmic surgical procedures and market growth over the next half-decade.
For the purposes of this report, the U.S. market for ophthalmic surgical systems includes sales derived from laser and phaco systems for vision correction and the minimally invasive treatment of cataracts, glaucoma, retinal, and other ophthalmic disorders. In addition to ophthalmic surgical systems sales, the market forecast includes revenues derived from surgical accessories/instruments and disposables utilized in minimally invasive directed energy-based ophthalmic surgery. In 2013, the U.S. ophthalmic surgical systems market was valued at approximately $1,695.8 million. Over the forecast period covered by this report, total sales in this market are expected to increase at a compound annual rate of 5.9%, reaching an estimated $2,256.4 million in the year 2018.
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. ophthalmic surgical systems market. Covered topics in this report include an overview of common ophthalmic diseases/disorders and therapies; U.S. procedure volumes; laser/phaco/energy-based surgical systems, next-generation laser-based systems and emerging technologies; and company profiles.
EXECUTIVE SUMMARY i. Clinical Overview a. Age-Related Macular Degeneration b. Cataracts c. Diabetic Retinopathy d. Glaucoma e. Refractive Errors ii. Market iii. Methodology 1. U.S. OPHTHALMIC SURGICAL SYSTEMS MARKET 1.1 Clinical Overview 1.1.1 Age-Related Macular Degeneration 1.1.2 Cataracts 1.1.3 Diabetic Retinopathy 1.1.4 Glaucoma 1.1.5 Refractive Errors 1.2 Ophthalmic Procedures 1.2.1 Age-Related Macular Degeneration 22.214.171.124 Anti-Angiogenic Therapy 126.96.36.199 Verteporfin Photodynamic Therapy 188.8.131.52 Transpupillary Thermotherapy 184.108.40.206 Retinal Photocoagulation 1.2.2 Cataract Surgery 220.127.116.11 Capsulotomy 18.104.22.168 Procedure Volumes Forecast 1.2.3 Diabetic Retinopathy Laser Surgery 22.214.171.124 Procedure Volumes Forecast 1.2.4 Glaucoma-Laser Trabeculoplasty 126.96.36.199 Procedure Volumes Forecast 1.2.5 Refractive Surgery 188.8.131.52 Laser-Based Vision Correction 184.108.40.206 Photorefractive Keratectomy 220.127.116.11 Laser In Situ Keratomileusis 18.104.22.168 Laser Epithelial Keratomileusis 22.214.171.124 Photoablative Inlay Laser In Situ Keratomileusis 126.96.36.199 Procedure Volumes Forecast 1.3 Market Analysis 1.3.1 Market Forecast 1.4 Competitive Analysis 1.4.1 Market Share Exhibit 1-1: 2013, Estimated U.S. Prevalence of Selected Ophthalmic Conditions Exhibit 1-2: Laser Therapy for Age-Related Macular Degeneration, U.S. Procedure Volumes Forecast, 2011-2018 Exhibit 1-3: Cataract Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) Exhibit 1-4: Diabetic Retinopathy Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) Exhibit 1-5: Glaucoma Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) Exhibit 1-6: Refractive Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) Exhibit 1-7: Selected Market Drivers and Limiters Exhibit 1-8: U.S. Ophthalmic Surgical Systems, Market Forecast, 2013-2018 Exhibit 1-9: 2013, U.S. Ophthalmic Surgical Systems Market, Estimated Percentage of Sales, by Application Exhibit 1-10: 2013, Leading Competitors in the U.S. Ophthalmic Surgical Systems Market and Applications for Leading Products Exhibit 1-11: 2013, U.S. Ophthalmic Surgical Systems Market, Share by Supplier 2. COMPANY PROFILES 2.1 Abbott Laboratories 2.1.1 Background 2.1.2 Abbott Medical Optics Division 2.1.3 Acquisitions 2.1.4 Surgical Systems 2.1.5 Medical Optics Revenues 2.1.6 Selected Financials 2.2 Carl Zeiss Meditec AG 2.2.1 Background 2.2.2 Carl Zeiss Ophthalmology Business 2.2.3 Acquisitions 2.2.4 Surgical Systems 2.2.5 Ophthalmology Segment Revenues 2.2.6 Selected Financials 2.3 IRIDEX Corporation 2.3.1 Background 2.3.2 Acquisitions/Divestitures 2.3.3 Surgical Systems 2.3.4 Selected Financials 2.4 Lumenis Ltd. 2.4.1 Background 2.4.2 Ophthalmic Division 2.4.3 Surgical Systems 2.4.4 Ophthalmic Division Revenues 2.4.5 Selected Financials 2.5 Novartis 2.5.1 Background 2.5.2 Alcon Division 2.5.3 Acquisitions 2.5.4 Surgical Systems 2.5.5 Alcon Division Revenues 2.5.6 Selected Financials 2.6 Valeant Pharmaceuticals 2.6.1 Background 2.6.2 Bausch and Lomb 2.6.3 Acquisitions 2.6.4 Surgical Systems 2.6.5 Bausch + Lomb Revenues 2.6.6 Selected Financials